Table 2 Recent clinical case reports of personalized phage therapy
From: Current status of bacteriophage therapy for severe bacterial infections
Organization/company | Country | Study | Year | Refs. |
|---|---|---|---|---|
Baylor college of medicine (TAILΦR) | USA | A retrospective, observational study. Device-related or systemic infections, 12 patients • Evaluated 12 cases of customized phage therapy, showing a 66% favorable response rate, with 42% bacterial eradication • Phage therapy was safe, though immunological neutralization occurred in some cases | 2023 | [20] |
Belgian Consortium Study | Belgium | A multicenter, multinational, retrospective observational study. Individualized phage therapy • Analyzed 100 cases of individualized phage therapy across 12 countries • Showed clinical improvement in 77.2% of cases and bacterial eradication in 61.3% • The use of antibiotics alongside phage therapy increased the likelihood of success | 2024 | [21] |
Prosthetic joint infections | Italy | A case report. Pa53 (anti-P. aeruginosa phage) • A 62-year-old patient with chronic P. aeruginosa infection was successfully treated with customized phage therapy and meropenem, showing no infection recurrence over 2 years | 2023 | [22] |
Diabetic foot infection | UK | A case series. Anti-S. aureus therapy • Tested anti-S. aureus phage therapy on 10 patients at high risk of amputation • Nine out of 10 patients benefited, though one patient showed no response to treatment | 2023 | [23] |
LVAD infection study | Israel/USA | A case series. Anti-P. aeruginosa therapy • Phage therapy in combination with antibiotics for LVAD-related P. aeruginosa infections had limited success, with breakthrough bacteremia and immune reactions hindering effectiveness | 2023 | [24] |